Pharma BD Deal Intelligence
Johnson & Johnson will acquire Momenta Pharmaceuticals for $52.50 per share in cash, or approximately $6.5 billion, gaining full global rights to nipocalimab,…
Johnson & Johnson announced a definitive agreement to acquire all outstanding shares of Momenta Pharmaceuticals, Inc. for $52.50 per share in cash,…
Johnson & Johnson today announced that it has completed its acquisition of Momenta Pharmaceuticals, Inc. through Vigor Sub, Inc., a wholly-owned subsidiary of…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Johnson & Johnson acquired Momenta Pharmaceuticals for approximately $6.5 billion ($52.50 per share in cash) via tender offer and merger, completed October 1, 2020, gaining nipocalimab (M281), an anti-FcRn antibody targeting autoantibody-driven diseases. The acquisition thesis has since been validated: on April 30, 2025 the FDA approved nipocalimab as IMAAVY (nipocalimab-aahu) for generalized myasthenia gravis (gMG) in adult and pediatric patients aged 12 and older who are anti-AChR or anti-MuSK antibody positive -- the first and only FcRn blocker approved across both antibody subtypes, based on the Phase 3 Vivacity-MG3 study. J&J is pursuing label expansion: it submitted an sBLA for warm autoimmune hemolytic anemia (wAIHA) in February 2026 (ENERGY Phase 2/3), for which the FDA granted Priority Review on April 27, 2026 as the potential first-ever approved wAIHA therapy, and nipocalimab holds Fast Track designation in Sjogren's disease. The asset has moved from pre-commercial pipeline to an approved, multi-indication FcRn franchise.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Johnson & Johnson / Momenta Pharmaceuticals Inc. (this deal) | 2020 | $6.5B | 72 |
| Johnson & Johnson / Legend Biotech Corporation | 2017 | $9.0B | 96 |
| Johnson & Johnson / Centocor Inc. | 1999 | $4.9B | 92 |
| Johnson & Johnson / Cougar Biotechnology, Inc. | 2009 | $970M | 91 |
| Johnson & Johnson / Actelion Ltd | 2017 | $30.0B | 90 |
| Johnson & Johnson / Aragon Pharmaceuticals Inc. | 2013 | $1.0B | 89 |
| Johnson & Johnson / Legend Biotech Corporation | 2017 | $350M | 83 |
← Browse all deals · How we score deals
More: 2020 deals · Johnson & Johnson deals · Immunology deals